Tag: property portfolio

Charles D. Young Appointed Chief Executive Officer and Appointed to the Board of Directors, Effective October 1, 2025;  Gary A. Shiffman to Transition to Non-Executive Chairman of the Board

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

EssilorLuxottica to acquire PUcore’s division dedicated to the development, manufacturing and sale of ophthalmic lens materials 

STRONG HALF-YEAR RESULTS WITH CONFIRMATION OF THE EXPECTED NET RESULT PER SHARE, DESPITE AN INCREASE IN THE NUMBER OF SHARES DUE TO THE OPTIONAL DIVIDEND

NAPLES, FL, July 14, 2025 (GLOBE NEWSWIRE) -- Music Licensing, Inc. (OTC: SONG) and its wholly owned subsidiary, Pro Music Rights, were recently featured in Bloomberg News and the Los Angeles Times in connection with national coverage on the rising costs and growing complexity of music licensing for restaurants and bars. The coverage highlights Pro Music Rights as a leading innovator among performance rights organizations (PROs), positioned to modernize an industry long dominated by legacy structures.

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET.

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

ORINDA, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (Nasdaq: MKZR) (“MacKenzie” or the “Company”) today announced the closing of a $3 million loan agreement with an institutional investor for the purchase of non-traded REIT shares.